Cardiac Safety of Citalopram: Prospective Trials and Retrospective Analyses
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The selective serotonin reuptake inhibitors (SSRIs) are believed to have a more benign cardiovascular safety profile than do the tricyclic antidepressants. The effects of the SSRI citalopram on cardiac conduction and repolarization have been extensively evaluated, both in prospective studies in volunteers and patients and in retrospective evaluations of all electrocardiographic (ECG) data from all clinical trials conducted from 1978 through 1996 (a total of 40 studies). A randomized, double-blind, placebo-controlled study was conducted in healthy volunteers (N = 23) to assess intraindividual variability of the QTc interval, as well as possible changes during treatment with placebo or citalopram, and its correlation to plasma drug levels. To document any dose-related changes, ECGs were performed at baseline and at the end of study in three randomized, double-blind, placebo- or active-controlled, fixed-dose trials in adult and elderly patients (N = 1,460) with major depression and/or dementia. Finally, more than 6,000 ECGs (N = 1,789 citalopram-treated patients) collected from all clinical trials conducted from 1978 through 1996 were reassessed in a standardized manner to identify any effects of citalopram on ECG parameters. Results of both prospective and retrospective analyses showed that the only effect of citalopram on ECG findings is a small reduction in heart rate (< or = 8 beats per minute). There were no significant effects on PQ, QRS, or QTc intervals, indicating that citalopram has no effect on cardiac conduction and repolarization during short- or long-term treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
'Vascular Depression' Hypothesis
Alexopoulos, G. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220033006 · Cited by 1,843
Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard‐Andersen, L., Gylding‐Sabroe, J., Kristensen, M., Refsum, H. ‐., Öfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258
Cited by
Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose
Isbister, G. K., Bowe, S. J., Dawson, A., & Whyte, I. M. (2004) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 435
QTc Prolongation, Torsades de Pointes, and Psychotropic Medications
Beach, S. R., Celano, C. M., Noseworthy, P. A., Januzzi, J. L., & Huffman, J. C. (2013) · Psychosomatics · doi:10.1016/j.psym.2012.11.001 · Cited by 345
Vieweg, W. V. R., Hasnain, M., Howland, R. H., Hettema, J. M., Kogut, C., Wood, M. A., & Pandurangi, A. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.002 · Cited by 270
Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg
Zivin, K., Pfeiffer, P. N., Bohnert, A. S. B., Ganoczy, D., Blow, F. C., Nallamothu, B. K., & Kales, H. C. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12030408 · Cited by 127
FDA drug safety communications: a narrative review and clinical considerations for older adults
Marcum, Z. A., Vande Griend, J. P., & Linnebur, S. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.05.002 · Cited by 85
Metadata
- Authors
- Rasmussen, S. L., Overø, K. F., & Tanghøj, P.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-10
- Volume
- 19
- Issue
- 5
- Pages
- 407-415
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1979204557
- Cited by
- 104
- References
- 2
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac Safety of Citalopram: Prospective Trials and Retrospective Analyses. https://app.cochat.ai/papers/10.1097/00004714-199910000-00004
- The paper
- Rasmussen, S. L., Overø, K. F., & Tanghøj, P. (1999). Cardiac Safety of Citalopram: Prospective Trials and Retrospective Analyses. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199910000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.